Rule, S http://orcid.org/0000-0001-8937-6351
Jurczak, W
Jerkeman, M
Rusconi, C
Trneny, M
Offner, F
Caballero, D
Joao, C
Witzens-Harig, M
Hess, G
Bence-Bruckler, I
Cho, S-G http://orcid.org/0000-0002-5429-4839
Thieblemont, C
Zhou, W
Henninger, T
Goldberg, J
Vermeulen, J
Dreyling, M
Article History
Received: 8 September 2017
Revised: 21 November 2017
Accepted: 22 December 2017
First Online: 2 February 2018
Compliance with ethical standards
:
: Conflicts of interestSR has served as an advisor for Janssen, Pharmacyclics and Napp, and has received research funding from Janssen. WJ has received research funding from Janssen and Pharmacyclics. MJ has received research funding from Janssen, Celgene, Abbvie and Gilead. CR has served as an advisor for Italfarmaco, Teva, Janssen, Takeda and Roche. MT has served as an advisor and received research funding from Janssen. CJ has served as an advisor for Celgene, Janssen, Takeda, Amgen and Roche. MW-H has served as an advisor and received honoraria from Janssen. GH has served as an advisor and received honoraria from Roche, Pfizer, Janssen, CTI and Celgene, and received research support from Roche, Pfizer, Mundipharma, Celgene and CTI. CT has served as an advisor for Bayer, Celgene, Janssen and Roche, and received research funding from Roche. MD has served as an advisor and received research funding from Janssen and Pfizer, and has received honoraria from Janssen. WZ is a contractor of Janssen. TH, JG and JV are employees of Janssen and own stocks in Johnson & Johnson. The remaining authors declare that they have no conflict of interest.